2024-03-19，美国临床肿瘤学会（ASCO）发布了晚期肝细胞癌（HCC）系统治疗指南更新，此次更新基于2020年ASCO晚期HCC系统治疗指南的8项Ⅲ期随机对照试验（RCT），并整合了近年最新的10项RCT研究数据，建议将阿替利珠单抗+贝伐珠单抗或度伐利尤单抗+替西木单抗作为肝功能Child-Pugh A级、美国东部肿瘤协作组体力活动状态评分0~1分的晚期HCC病人的首选一线治疗方案，同时也解答了晚期HCC不同一线方案治疗后的二线及后线治疗的选择。

On March 19, 2024, the American Society of Clinical Oncology (ASCO) released an update to the guidelines for the systemic treatment of advanced hepatocellular carcinoma (HCC). This update, based on eight phase Ⅲrandomized controlled trials (RCTs) from the 2020 ASCO guidelines, integrated ten latest RCT data in recent years and recommended atezolizumab plus bevacizumab or durvalumab plus tremelimumab as the preferred first-line treatment for advanced HCC patients with Child-Pugh A status and ECOG PS 0-1. It also addressed the selection of second-line and subsequent-line treatments for advanced HCC patients.